|
Q3 FY2026
As of Aug 31, 2026
|
Q2 FY2026
As of May 31, 2026
|
Q1 FY2026
As of Feb 28, 2026
|
Q4 FY2025
As of Nov 30, 2025
|
Q3 FY2025
As of Aug 31, 2025
|
Q2 FY2025
As of May 31, 2025
|
Q1 FY2025
As of Feb 28, 2025
|
Q4 FY2024
As of Nov 30, 2024
|
Q3 FY2024
As of Aug 31, 2024
|
Q2 FY2024
As of May 31, 2024
|
Q1 FY2024
As of Feb 29, 2024
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| CURRENT ASSETS | |||||||||||
| Cash and cash equivalents | |||||||||||
| Amount due from a shareholder | |||||||||||
| Amount due from related party | |||||||||||
| Accounts Receivable | |||||||||||
| Prepayments and deposit | |||||||||||
| TOTAL CURRENT ASSETS | |||||||||||
| NON-CURRENT ASSET | |||||||||||
| Plant and equipment, net | |||||||||||
| TOTAL NON-CURRENT ASSET | |||||||||||
| TOTAL ASSETS | |||||||||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||||||||||
| CURRENT LIABILITIES | |||||||||||
| Accrued liabilities and other payable | |||||||||||
| Amount due to a director | |||||||||||
| Amount due to a shareholder | |||||||||||
| Director | |||||||||||
| Total amount due to a shareholder | |||||||||||
| Deferred revenue | |||||||||||
| Contract liabilities | |||||||||||
| TOTAL CURRENT LIABILITIES | |||||||||||
| TOTAL LIABILITIES | |||||||||||
| SHAREHOLDERS’ EQUITY | |||||||||||
| Common stock – Par value $ 0.001; Authorized: 75,000,000 shares; Issued and outstanding: 44,545,000 and 44,545,000 as of August 31, 2026 and November 30, 2025, respectively | |||||||||||
| Share application money pending allotment | |||||||||||
| Additional paid-in capital | |||||||||||
| Accumulated deficit | |||||||||||
| Accumulated comprehensive loss | |||||||||||
| TOTAL SHAREHOLDERS’ DEFICIT | |||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
Loading...
